局部晚期乳腺癌新辅助化疗后前哨淋巴结活检的前瞻性研究
该前瞻性研究评估局部晚期乳腺癌患者新辅助化疗后前哨淋巴结活检的假阴性率。在145例入组患者中,87例实现充分定位,前哨淋巴结假阴性率为2.1%(95%CI 0.1-12.7),提示新辅助化疗降期后前哨淋巴结活检或可用于腋窝分期。
要点
- 局部晚期乳腺癌新辅助化疗后前哨淋巴结识别率为74%。
- 充分定位患者中前哨淋巴结假阴性率为2.1%(95%CI 0.1-12.7)。
- 前哨淋巴结活检或可作为新辅助化疗降期后腋窝分期方法。
核心结论
- 在局部晚期乳腺癌前瞻性队列中,前哨淋巴结识别率为74%,假阴性率为2.1%,提示新辅助化疗降期后前哨淋巴结活检或可适用于腋窝分期。
研究设计与样本
- 前瞻性队列研究,计划入组150例,实际入组145例cT4和/或cN2/N3且新辅助化疗后达临床淋巴结完全缓解的乳腺癌患者。
- 前哨淋巴结活检采用双示踪剂定位,不要求淋巴结夹标,所有患者均行完成性腋窝淋巴结清扫。
主要发现
- 456例患者筛查,369例(81%)新辅助化疗后达cN0,145例入组。
- 入组患者中44%为炎性乳腺癌(cT4d),23%为其他cT4病变,12%为cN2,21%为cN3。
- 108例(74%)至少识别1枚前哨淋巴结,其中87例定位充分(≥3枚前哨淋巴结82例,1-2枚前哨淋巴结加夹标淋巴结5例)。
- 87例定位充分患者中,淋巴结病理完全缓解率为46%;47例(54%)有残留淋巴结病变,观察到1例前哨淋巴结假阴性,假阴性率为2.1%(95%CI 0.1-12.7)。
临床怎么用
- 对于新辅助化疗后达临床淋巴结完全缓解的局部晚期乳腺癌患者,可考虑采用双示踪剂前哨淋巴结活检进行腋窝分期。
局限性
- 前哨淋巴结识别率仅为74%,部分患者无法成功定位。
- 假阴性率95%CI上限达12.7%,样本量有限,精确度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To prospectively determine the false-negative rate (FNR) of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer (LABC). METHODS: Patients with cT4 and/or cN2/N3 breast cancer with a nodal complete response (cN0) after NAC were eligible. SLNB was performed with dual-tracer mapping; nodal clipping was not required. All patients had a completion axillary lymph node dissection. FNR calculations were based on the patients with adequate mapping (ie, ≥3 SLNs or <3 SLNs plus clipped node). Of the planned 150 patients, we anticipated that 84 patients would have adequate mapping and that 47 would have residual disease after NAC (nodal pathologic complete response [pCR] rate: 45%). Assuming a true FNR of 10%, we estimated that this sample size would allow estimation of FNR within a margin of error (95% CI half-width) of ±8.6%. RESULTS: From August 2017 to December 2025, 456 patients were screened for eligibility; 369 (81%) became cN0 after NAC and 145 were enrolled in the study. Of these, 44% of patients had inflammatory breast cancer (cT4d), 23% had other cT4 disease, 12% had cN2 disease, and 21% had cN3 disease. At least 1 SLN was identified in 108 patients (74%), of whom 87 had either ≥3 SLNs (n = 82) or 1-2 SLNs with a clipped node retrieved (n = 5). Of 87 patients with adequate mapping, the nodal pCR rate was 46%; of 47 (54%) with residual nodal disease, one false-negative SLN was observed, yielding an SLN FNR of 2.1% (95% CI, 0.1 to 12.7). CONCLUSION: In a prospective cohort of patients with LABC, the SLN identification rate was 74% and the FNR was 2.1%, suggesting that SLNB may be an appropriate method to stage the axilla in LABC after downstaging with NAC.
引用
- Barrio AV, Mautner S, Capko D, et al. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer. J Clin Oncol. 2026. PMID: 42809799. doi:10.1200/JCO-26-01114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。